The illness sends tens of thousands of babies to the hospital each year. If approved, the new injection would be the first broadly available prevention tool.

The White House asked for more money from Congress to keep its COVID response going. But that hasn't happened, so some things need to be wound down.

The medicines from Eli Lilly and Regeneron are infused, a process that can take two hours or longer, including observation for side effects. Staffing is as big an issue as the supply of the drugs.

The secretary of the Department of Housing and Urban Development says in a Facebook post that he credits monoclonal antibody treatments with helping him recover from COVID-19.

Eli Lilly's monoclonal antibody will be available to people 65 or older or those with underlying health conditions. Supplies will be short, and allocating the medicine will be a challenge.

The federal government plans to distribute 300,000 doses of the drug at no cost, but that doesn't mean treatment will be free. Intravenous infusion charges can run more than $1,000.

The trial studied the efficacy of bamlanivimab in combination with the antiviral remdesivir on hospitalized COVID-19 patients. Researchers concluded the antibody treatment was "unlikely to help."